Guideline Video
Guideline Resources
- Use of Prolonged-Infusion Beta-Lactam Antibiotics
- American College of Clinical Pharmacy, Cystic Fibrosis Foundation, Infectious Diseases Society of America, Society of Infectious Diseases Pharmacists, and Society of Critical Care Medicine
- August 14, 2026
- Summary
- Full-text
Video Transcription
Just published August 14th, 2026, the American College of Clinical Pharmacy, Cystic Fibrosis Foundation, Infectious Diseases Society of America, Society of Infectious Diseases Pharmacists, and Society of Critical Care Medicine’s newest consensus on Use of Prolonged-Infusion Beta-Lactam Antibiotics.
This consensus aims to update recommendations associated with clinically important efficacy outcomes in severely ill adult patients.
In today’s rapid update, we’ll just be going over a summary of updated recommendations from this consensusohhh so for the full consensus, make sure to check it out on guidelinecentral.com
Let’s get started.
- The consensus suggests prolonged-infusion β-lactam antibiotics over short infusions to reduce mortality among severely ill adult patients, particularly those with Gram-negative infections.
- The consensus suggests prolonged-infusion β-lactam antibiotics over short infusions to increase clinical cure among severely ill adult patients, particularly those with Gram-negative infections.
- When initiating continuous infusion β-lactams in severely ill patients, the consensus suggests administering a loading dose to improve clinical success; for extended infusion, evidence is insufficient to recommend for or against a loading dose.
And there you have it. Make sure to check out the full consensus from the American College of Clinical Pharmacy, Cystic Fibrosis Foundation, Infectious Diseases Society of America, Society of Infectious Diseases Pharmacists, and Society of Critical Care Medicine and other related clinical decision support tools at guidelinecentral.com.
Sign up for alerts and stay informed on the latest published articles and guidelines.